title: Effects of omega-3 fatty acids supplementation on serum adiponectin levels and some metabolic risk factors in women with polycystic ovary syndrome.
abstract: OBJECTIVE
  Polycystic ovary syndrome (PCOS) is a common female endocrine disorder associated with several risk factors of type 2 diabetes and cardiovascular diseases. The objectives of this study were to investigate the effects of omega-3 fatty acids on serum adiponectin levels and some metabolic risk factors in PCOS patients.
  
  
  METHODS
  This double-blind randomized controlled clinical trial was conducted on 64 overweight or obese PCOS patients; aged 20-35 years. Subjects in omega-3 fatty acids (n=32) and placebo (n=32) groups were given 4 omega- 3 fatty acids capsules (each one contained 180 mg eicosapentaenoic acid and 120 mg docosahexanoic acid) or placebo daily for 8 weeks. Fasting blood samples, anthropometric measurements and 3-day, 24-hour dietary recalls were collected at the baseline and at the end of the trial.
  
  
  RESULTS
  The study was completed by 61 subjects. Omega-3 fatty acids significantly increased serum levels of adiponectin (p=0.003) and decreased glucose (p<0.001), insulin (p=0.002), homeostatic model assessment for insulin resistance (p<0.001), total cholesterol (p=0.002) and low-density lipoprotein cholesterol (p=0.003) compared with placebo. Serum levels of triglyceride significantly decreased (p=0.024) and high-density lipoprotein cholesterol increased (p=0.018) in the omega-3 fatty acids group, in comparison with baseline values. No significant changes were shown in serum high sensitive C-reactive protein (hs-CRP) levels in both groups.
  
  
  CONCLUSIONS
  Omega-3 fatty acids had some beneficial effects on serum adiponectin levels, insulin resistance and lipid profile in PCOS patients and may contribute to the improvement of metabolic complications in these patients.
authors.affiliation: Students' Research Committee, Faculty of Health & Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Elahe
authors.initials: E
authors.lastname: Mohammadi
authors.forename: Maryam
authors.initials: M
authors.lastname: Rafraf
authors.forename: Laya
authors.initials: L
authors.lastname: Farzadi
authors.forename: Mohammad
authors.initials: M
authors.lastname: Asghari-Jafarabadi
authors.forename: Siamak
authors.initials: S
authors.lastname: Sabour
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000328:Adult; D015992:Body Mass Index; D019587:Dietary Supplements; D004311:Double-Blind Method; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology / Q000517:prevention & control; D007333:Insulin Resistance; D007492:Iran / Q000453:epidemiology; D008055:Lipids / Q000097:blood; D024821:Metabolic Syndrome / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D009765:Obesity / Q000150:complications; D050177:Overweight / Q000150:complications; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications / Q000208:ethnology / Q000503:physiopathology; D012307:Risk Factors; D055815:Young Adult
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D015525:Fatty Acids, Omega-3; D008055:Lipids